(Q36712243)

15 August 2017

Novel approaches to corticosteroid treatment in Duchenne muscular dystrophy (English)

1 reference

Duchenne muscular dystrophy

15 August 2017

1 reference

4

Kanneboyina Nagaraju

1 reference

15 August 2017

1

Eric P Hoffman

1 reference

15 August 2017

Erica Reeves

2

1 reference

15 August 2017

Jesse Damsker

3

1 reference

15 August 2017

John M McCall

5

1 reference

15 August 2017

Edward M Connor

6

1 reference

15 August 2017

Kate Bushby

7

1 reference

15 August 2017

1 November 2012

1 reference

Physical medicine and rehabilitation clinics of North America

15 August 2017

1 reference

15 August 2017

23

1 reference

15 August 2017

4

1 reference

15 August 2017

821-828

1 reference

Δ-9,11 modification of glucocorticoids dissociates nuclear factor-κB inhibitory efficacy from glucocorticoid response element-associated side effects.

15 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Glucocorticoid-induced myopathy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

A robust in vitro screening assay to identify NF-kappaB inhibitors for inflammatory muscle diseases

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Glucocorticoid corticosteroids for Duchenne muscular dystrophy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Separating transrepression and transactivation: a distressing divorce for the glucocorticoid receptor?

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

The role of corticosteroids in muscular dystrophy: a critical appraisal

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Antiinflammatory action of glucocorticoids--new mechanisms for old drugs

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Practice parameter: corticosteroid treatment of Duchenne dystrophy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Calcium influx inhibition by steroids and analogs in C2C12 skeletal muscle cells

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord I

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

The mechanism of cytoprotective action of lazaroids I: Inhibition of reactive oxygen species formation and lethal cell injury during periods of energy depletion.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Steroids in Duchenne muscular dystrophy; pilot study of a new low-dosage schedule

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Complete cloning of the duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Dystrophin: the protein product of the Duchenne muscular dystrophy locus

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Use of corticosteroids in a population-based cohort of boys with duchenne and becker muscular dystrophy

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Intermittent prednisone therapy in Duchenne muscular dystrophy: a randomized controlled trial

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Balancing muscle hypertrophy and atrophy

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

High dose weekly oral prednisone improves strength in boys with Duchenne muscular dystrophy.

5 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3606917

Steroids in duchenne muscular dystrophy — Deflazacort trial

5 September 2018

1 reference

12 December 2020

Long-Term Steroid Therapy in Duchenne Muscular Dystrophy-Positive Results versus Side Effects

1 reference

12 December 2020

Antioxidant activity of U-83836E, a second generation lazaroid, during myocardial ischemia/reperfusion injury

1 reference

12 December 2020

Deflazacort in Duchenne dystrophy: study of long-term effect

1 reference

12 December 2020

A comparison of daily and alternate-day prednisone therapy in the treatment of Duchenne muscular dystrophy

1 reference

12 December 2020

Prednisone in Duchenne dystrophy. A randomized, controlled trial defining the time course and dose response. Clinical Investigation of Duchenne Dystrophy Group

1 reference

12 December 2020

Duchenne dystrophy: randomized, controlled trial of prednisone (18 months) and azathioprine (12 months)

1 reference

12 December 2020

Clinical investigation of Duchenne muscular dystrophy. Interesting results in a trial of prednisone

1 reference

12 December 2020

A multicenter, double-blind, randomized trial of deflazacort versus prednisone in Duchenne muscular dystrophy

1 reference

12 December 2020

10.1016/J.PMR.2012.08.003

Identifiers

DOI

1 reference

15 August 2017

1 reference

15 August 2017

PubMed publication ID

23137739

1 reference